Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
Study sponsor: Abivax S.A. · ABVX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2021-04-01Actual
Enrollment · participants355Actual
Source updated2025-11-28Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.